Silymarin
Hepatoprotective FlavonolignanPreclinicalAlso known as: Milk Thistle Extract, Silybum marianum, Silibinin, Silybin, Legalon, Siliphos, IdB1016, Silipide
Silymarin is the standardized flavonolignan complex extracted from the seeds (technically the fruit, or achenes) of milk thistle — Silybum marianum — a thistle native to the Mediterranean basin now naturalized across Europe, North Africa, North and South America, and Australia. Silymarin is not a single molecule but a defined mixture of six closely related flavonolignans: silybin A, silybin B (together called silibinin, the dominant and most pharmacologically active pair, representing roughly 50–70% of the silymarin complex), isosilybin A, isosilybin B, silychristin, and silydianin, along with minor constituents including taxifolin (the biosynthetic flavonoid precursor) and small quantities of apigenin-7-glucoside and other flavonoids.
Overview
At A Glance
Silymarin's hepatoprotective and systemic effects organize around seven interlocking mechanisms that distinguish it from both classical pharmaceuticals and other botanical hepatoprotectants.…
Mechanism of Action
Silymarin's hepatoprotective and systemic effects organize around seven interlocking mechanisms that distinguish it from both classical pharmaceuticals and other botanical hepatoprotectants.
(1) Hepatocyte membrane stabilization and toxin uptake blockade. The single most clinically consequential mechanism of silymarin — and the mechanism underpinning its life-saving role as the IV antidote for amatoxin poisoning — is its ability to bind to and stabilize the hepatocyte plasma membrane, particularly at the sinusoidal (basolateral) surface where hepatic uptake transporters reside. Silibinin (the primary active isomer pair in silymarin) is a potent competitive inhibitor of OATP1B1 (organic anion transporting polypeptide 1B1, encoded by SLCO1B1) and OATP1B3 (SLCO1B3) — the major basolateral uptake transporters that carry bile acids, bilirubin, many drugs, and critically, the Amanita phalloides toxin α-amanitin into hepatocytes. By blocking OATP-mediated hepatocyte uptake, IV silibinin dihydrogensuccinate (Legalon SIL) prevents ongoing uptake of amatoxins from the circulation, interrupting the enterohepatic recycling that otherwise delivers repeated lethal doses to the liver over 24–48 hours following mushroom ingestion. Mengs 2012summarizes the European observational experience with Legalon SIL in amatoxin poisoning, with mortality reductions substantial enough to establish silibinin IV as standard of care. This same mechanism — OATP inhibition — explains some silymarin drug interactions (modestly elevated plasma levels of statins and other OATP substrates) and underlies silymarin's general hepatoprotective effect against any toxin that enters hepatocytes via OATPs.
(2) Free radical scavenging and lipid peroxidation inhibition. Silibinin is a potent phenolic antioxidant with multiple hydroxyl groups capable of donating hydrogen atoms to peroxyl, hydroxyl, superoxide, and hypochlorous acid radicals. In hepatocytes, silymarin reduces lipid peroxidation (measured as malondialdehyde, 4-hydroxynonenal, or conjugated dienes), protects membrane polyunsaturated fatty acids from oxidation, and interrupts the propagation of radical chain reactions during toxic insult. The direct-scavenging activity is most relevant during acute oxidative stress (ethanol metabolism, carbon tetrachloride exposure, acetaminophen overdose, ischemia-reperfusion injury), where rapid radical generation would otherwise overwhelm endogenous antioxidant defenses. Silymarin shares this general radical-scavenging mechanism with other phenolic antioxidants (quercetin, hydroxytyrosol, EGCG, resveratrol) but its distinctive location of action is the hepatocyte itself, where silymarin and its conjugates reach their highest concentrations due to enterohepatic recycling.
(3) Glutathione replenishment and Nrf2 activation. Silymarin increases hepatic glutathione (GSH) content through two complementary mechanisms: it reduces GSH consumption (by scavenging radicals that would otherwise deplete GSH during detoxification) and it increases GSH synthesis by upregulating γ-glutamylcysteine ligase (GCL), the rate-limiting enzyme for GSH biosynthesis. The GCL upregulation is driven in part by silymarin's activation of Nrf2 (nuclear factor erythroid 2-related factor 2), the transcription factor that controls antioxidant response element (ARE)-driven gene expression. Silymarin covalently modifies cysteine residues on Keap1 (the cytosolic Nrf2 inhibitor), allowing Nrf2 to translocate to the nucleus and upregulate phase-II detoxification and antioxidant enzymes: heme oxygenase-1 (HO-1), NAD(P)H:quinone oxidoreductase-1 (NQO1), glutathione-S-transferases (GSTs), thioredoxin reductase, and the superoxide dismutases. This Nrf2 activation is shared with sulforaphane (more potent Nrf2 activator), curcumin, and hydroxytyrosol, and explains silymarin's "preconditioning" or "priming" effect — protection against subsequent oxidative insult that persists beyond the brief circulating half-life of the parent molecule.
(4) Protein synthesis induction and hepatocyte regeneration. Silibinin stimulates ribosomal RNA polymerase I (Pol I) activity in hepatocyte nuclei, increasing rRNA synthesis and consequently ribosomal protein synthesis. This accelerates hepatocyte regeneration after injury — the liver has extraordinary regenerative capacity (a single healthy lobe can regenerate to full liver mass in weeks after hepatectomy), but this regeneration is metabolically demanding and requires rapid ribosomal biogenesis. The Pol I stimulation was first demonstrated by Sonnenbichler in the 1970s–1980s in isolated hepatocyte nuclei and later confirmed in vivo in models of partial hepatectomy and toxic liver injury. Clinically, this mechanism is most relevant in the recovery phase after acute hepatotoxic exposure and in the regenerative response in chronic low-grade injury patterns like NAFLD.
(5) Anti-inflammatory activity via NF-κB and 5-lipoxygenase inhibition. Silymarin inhibits NF-κB activation in hepatocytes, Kupffer cells (hepatic macrophages), and hepatic stellate cells, reducing transcription of pro-inflammatory cytokines (TNF-α, IL-6, IL-1β), chemokines (MCP-1, CXCL1), and acute-phase proteins. Silibinin also inhibits 5-lipoxygenase (5-LOX), the enzyme that converts arachidonic acid to leukotrienes (LTB4, LTC4, LTD4), reducing leukotriene-mediated neutrophil recruitment and leukotriene-driven inflammation. Combined NF-κB and 5-LOX inhibition produces the anti-inflammatory signal that contributes to silymarin's signal in NAFLD, chronic hepatitis, and drug-induced liver injury.
(6) Antifibrotic activity via hepatic stellate cell modulation. Chronic liver injury activates hepatic stellate cells (HSCs), quiescent vitamin A-storing cells in the space of Disse that transdifferentiate into myofibroblasts upon activation and deposit collagen (primarily type I and III), leading to fibrosis and, ultimately, cirrhosis. Silibinin reduces TGF-β signaling in HSCs (the master pro-fibrotic cytokine), inhibits HSC proliferation, and reduces collagen deposition in animal models of bile-duct ligation, carbon tetrachloride-induced fibrosis, and thioacetamide models. The clinical relevance in humans is supported by several trials showing modest reductions in non-invasive fibrosis markers (FibroScan elastography, APRI, FIB-4) after 6–12 months of silymarin supplementation in NAFLD cohorts, though effect sizes are modest relative to established antifibrotic strategies (weight loss, direct-acting antivirals in HCV).
(7) Weak CYP450 and transporter modulation with clinical implications. Silymarin is a weak inhibitor of CYP3A4, CYP2C9, and P-glycoprotein at typical supplemental doses, with more pronounced inhibition at very high doses. The CYP effects are clinically minor for most drugs but can become relevant in specific contexts: narrow-therapeutic-index drugs metabolized by CYP3A4 (tacrolimus, cyclosporine, some chemotherapeutics) may require modest dose adjustment; CYP2C9-metabolized drugs (warfarin, phenytoin, sulfonylureas) warrant monitoring during initiation. The OATP1B1 inhibition (above) can modestly elevate statin plasma levels, particularly rosuvastatin, atorvastatin, and simvastatin; this is usually clinically insignificant but worth monitoring if new myalgia develops after adding silymarin. Silymarin is itself extensively metabolized by UGT glucuronidation (primarily UGT1A1 and UGT1A8) and sulfation; this phase-II metabolism is the basis for most of the pharmacokinetic challenges in achieving high circulating silibinin levels with oral dosing.
Integration. The net effect of silymarin in a chronically injured liver is a multifactorial protection: reduced toxin uptake (mechanism 1), reduced oxidative damage (2 and 3), enhanced regenerative capacity (4), reduced inflammation (5), slowed fibrosis progression (6), and modest modulation of drug metabolism (7). This mechanistic breadth explains why silymarin shows efficacy signals across a wide range of liver injury patterns but also why its effect sizes are modest relative to targeted pharmaceuticals — it is hitting many nodes gently rather than any single node hard. In the contemporary NAFLD / MAFLD context, silymarin's mechanisms align particularly well with the pathophysiology: oxidative stress from hepatic lipotoxicity, mitochondrial dysfunction, low-grade inflammation, and stellate cell activation driving slow progression to NASH and fibrosis. This mechanistic alignment — combined with excellent safety and no meaningful contraindication with concurrent metabolic medications (metformin, GLP-1 agonists, SGLT2 inhibitors, statins) — makes silymarin a defensible daily-use agent in the expanding population of users managing metabolic liver disease alongside lifestyle and pharmacologic interventions.
Overview
Silymarin is the standardized flavonolignan complex extracted from the seeds (technically the fruit, or achenes) of milk thistle — Silybum marianum — a thistle native to the Mediterranean basin now naturalized across Europe, North Africa, North and South America, and Australia. Silymarin is not a single molecule but a defined mixture of six closely related flavonolignans: silybin A, silybin B (together called silibinin, the dominant and most pharmacologically active pair, representing roughly 50–70% of the silymarin complex), isosilybin A, isosilybin B, silychristin, and silydianin, along with minor constituents including taxifolin (the biosynthetic flavonoid precursor) and small quantities of apigenin-7-glucoside and other flavonoids. The United States Pharmacopeia (USP) defines standardized milk thistle extract as containing 70–80% silymarin, of which silibinin should constitute at least 30% of the total. European Medicines Agency and German Commission E monographs establish parallel standards. This standardization matters because "milk thistle" products vary in potency by more than an order of magnitude depending on extraction method, cultivar, and whether the product is standardized at all — non-standardized seed powder in bulk capsules bears little resemblance to clinical-trial standardized extracts.
Silymarin is the most extensively studied, most widely used, and most pharmacologically consequential hepatoprotective natural product in the Western materia medica. Its use in liver disease traces back to Pliny the Elder (1st century CE) and Dioscorides, was codified in German phytomedicine in the 1960s following chemical characterization by Wagner and colleagues, and has since generated more than 1,000 peer-reviewed publications — including pharmacokinetic studies, mechanistic work, animal models of virtually every major liver injury pattern, and dozens of randomized controlled trials in humans. In Germany and several European countries, silymarin is a registered pharmaceutical product (Legalon, Madaus) with specific indications for toxic and chronic inflammatory liver disease; in the United States, it is sold as a dietary supplement under the Dietary Supplement Health and Education Act (DSHEA) framework but remains one of the few botanicals to have undergone NIH-funded Phase III trials. The intravenous form — silibinin dihydrogensuccinate (Legalon SIL) — holds FDA orphan drug designation and is the first-line antidote for Amanita phalloides (death cap mushroom) poisoning, a condition in which its ability to block hepatocyte uptake of the amatoxin via OATP transporters is genuinely life-saving.
BodyHackGuide covers silymarin as the canonical liver-support agent alongside TUDCA (the bile-acid hepatoprotectant with FXR and ER-stress mechanisms), glutathione (the master intracellular antioxidant that silymarin upregulates), N-acetylcysteine (the glutathione precursor and acetaminophen-overdose antidote), and alpha-lipoic-acid (the mitochondrial antioxidant that stacks well with silymarin for hepatic and metabolic effect). Silymarin's role in the contemporary longevity and metabolic-health stack has expanded well beyond its classical hepatitis indication. It is now routinely used as: (1) a daily liver-support supplement in users with non-alcoholic fatty liver disease (NAFLD / MASLD, the most prevalent chronic liver disease worldwide, affecting roughly 25–30% of adults globally), (2) a protective agent alongside hepatotoxic medications (statins, methotrexate, tuberculosis drugs, antiretrovirals, long-term acetaminophen use), (3) an adjunct in alcohol-related liver disease, (4) a component of longevity protocols for users whose hepatic reserve is under metabolic stress from aging, high dietary burden, or xenobiotic exposure, and (5) a hangover-mitigation ingredient — though the evidence for acute alcohol mitigation is less strong than the chronic liver-protection evidence.
The clinical evidence base for silymarin spans roughly 50 years and supports several distinct use cases with differing strength of evidence. The strongest evidence is for amatoxin poisoning (where IV silibinin dihydrogensuccinate is effectively curative and is EMA-approved for this indication). The next strongest is for NAFLD / non-alcoholic steatohepatitis (NASH / MASH), where multiple RCTs — including the Loguercio 2012 multicenter trial of silybin-phosphatidylcholine-vitamin E (Realsil, IdB1016-based) and earlier pilot studies — have shown improvements in liver enzymes (ALT, AST, GGT), hepatic echogenicity on ultrasound, and in some trials modest improvements in HOMA-IR and liver histology. Chronic hepatitis C evidence is mixed: Ferenci 1989 (PMID 2671116) showed survival benefit in alcoholic cirrhosis; Fried 2012, the large NIH-funded SYNCH trial of oral silymarin 420 or 700 mg TID in HCV patients with prior interferon failure, failed to show significant ALT improvement at the doses tested — although pharmacokinetic substudies (Hawke 2010) indicate the oral doses studied may not have achieved therapeutically relevant plasma silibinin levels. Evidence for drug-induced liver injury prevention (methotrexate, tacrine, antitubercular regimens) is consistent but drawn from small trials. Evidence for alcoholic liver disease is historically positive (Ferenci 1989, Parés 1998) but newer trials are fewer, in part because the clinical priority has shifted toward alcohol cessation rather than pharmacologic rescue.
Commercially, silymarin is available in several forms with meaningfully different bioavailability profiles. Standardized milk thistle extract — 70–80% silymarin with ≥30% silibinin — is the baseline form, sold in capsules typically dosing 150–300 mg of the extract (delivering 105–240 mg silymarin, of which 30–70 mg is silibinin). The major limitation of baseline silymarin is poor oral bioavailability: parent silibinin has absolute oral bioavailability of roughly 0.73–7.5%, with most of the dose either not absorbed, rapidly conjugated to glucuronides and sulfates that retain some activity, or subject to enterohepatic recycling. This bioavailability problem has driven the development of enhanced delivery systems. Siliphos (branded IdB1016 from Indena, Italy) is silybin-phosphatidylcholine complex (sometimes called silybin phytosome), first described by Bombardelli and colleagues in 1991, which increases silibinin Cmax roughly 4–10 fold and AUC roughly 4–7 fold over baseline silibinin. Silipide is a similar phytosome formulation. Legalon (Madaus) uses a specific extraction and formulation process validated across European clinical trials. Thisilyn (Nature's Way) is a widely available US standardized extract. Jarrow Formulas Milk Thistle, NOW Foods Milk Thistle Silymarin, Life Extension European Milk Thistle (Silybin Advanced), and Solgar Milk Thistle are additional common products. For serious therapeutic intent (NAFLD, hepatitis, post-hepatotoxic drug exposure), phytosome forms (Siliphos) are strongly preferred; for general daily liver support, a well-standardized 80% silymarin extract at 200–300 mg/day is adequate and cost-effective.
Silymarin occupies an unusual position in pharmacology: it is a natural product with mechanistic depth (membrane stabilization, antioxidant, antifibrotic, anti-inflammatory, regenerative, anti-apoptotic, and anti-viral activities all documented in vitro and in animal models), decades of human use including hospital-grade IV formulation for acute amatoxin poisoning, orphan drug designation, and a generally benign safety profile — yet its clinical effect sizes in common chronic liver conditions are modest, and the pharmacokinetic challenges of oral absorption have limited the achievable plasma concentrations in ambulatory use. The result is a compound that is reliably safe, mechanistically well-characterized, probably beneficial for most hepatic indications, but not transformative as a monotherapy for severe liver disease. For the BodyHackGuide user, silymarin is best understood as a tier-1 liver-support ingredient — one of the single most defensible daily-use hepatoprotectants in the natural-product space — that pairs naturally with TUDCA, NAC, choline, and a Mediterranean-diet polyphenol pattern for durable long-term hepatic health. It is not a substitute for cessation of hepatotoxic exposure, for weight loss in MAFLD, for antiviral therapy in active hepatitis, or for specialist care in progressive liver disease, but it is a reasonable and generally supportable adjunct across those contexts.
Chemical Information
IUPAC Name
Not yet available
CAS Number
Not yet available
Molecular Formula
Not yet available
Molecular Mass
Not yet available
Chemical data is being compiled for this compound.
Dosing & Protocols
Unlock Dosing Protocols
Free account gets you:
- View beginner, intermediate & advanced protocols
- See weight-based dosing calculations
- Access cycle length & frequency data
2,800+ researchers already in
Research
Unlock Research Data
Free account gets you:
- Browse PubMed study summaries
- See clinical trial phases & results
- Access mechanism of action details
2,800+ researchers already in
Interactions
Contraindications
Silymarin has very few absolute contraindications and is among the most benign botanical extracts in common use. Relative contraindications and cautions:
True Compositae / Asteraceae allergy. Milk thistle is in the Asteraceae (Compositae) plant family. Users with severe allergy to ragweed, chrysanthemum, daisy, marigold, chamomile, echinacea, artichoke, or feverfew may cross-react with milk thistle — oral allergy syndrome, urticaria, and (rarely) anaphylaxis have been documented. For mild Compositae sensitivity: start with 75–150 mg once daily for 1 week, monitor for oral tingling, lip itching, or skin reactions, escalate only if tolerated. For severe Compositae allergy with anaphylaxis history: avoid entirely or test under allergist supervision.
Pregnancy and lactation. Moderate traditional use of milk thistle in pregnancy and lactation exists across European phytotherapy, with long-standing use as a galactagogue (to stimulate milk production in lactation). Modern pharmacokinetic and teratogenicity data in humans is limited. Animal reproductive studies are reassuring. A reasonable approach: moderate doses (150–300 mg standardized silymarin/day) during pregnancy and lactation appear safe based on long use, but the absence of modern controlled data warrants discussion with obstetrician/pediatrician and preference for moderate over high-dose regimens. Avoid high-dose phytosome forms (>480 mg/day) during pregnancy without specific indication and OB oversight.
Concurrent antidiabetic therapy. Silymarin has modest insulin-sensitizing effects. Users on insulin, sulfonylureas (glyburide, glipizide, glimepiride), or meglitinides (repaglinide, nateglinide) may experience mild additive hypoglycemic effect during the first 2–4 weeks of silymarin initiation. Monitor blood glucose; adjust antihyperglycemic dose downward as needed with your prescribing physician. Metformin, SGLT2 inhibitors, and GLP-1 agonists have minimal hypoglycemia risk and typically do not require adjustment.
Concurrent warfarin therapy. Silymarin is a weak inhibitor of CYP2C9, the primary metabolizing enzyme for the more-potent S-warfarin enantiomer. Modest elevations of INR can occur in some patients during the first 2–3 weeks of silymarin initiation. Practical approach: check INR 2–3 weeks after adding silymarin to stable warfarin therapy; adjust warfarin dose if INR rises above target range. DOACs (apixaban, rivaroxaban, dabigatran, edoxaban) have minimal interaction and do not require monitoring adjustment.
Concurrent cyclosporine or tacrolimus therapy. Silymarin's weak CYP3A4 inhibition can modestly elevate cyclosporine and tacrolimus plasma levels. In transplant recipients or autoimmune patients on calcineurin inhibitors, coordinate addition of silymarin with the prescribing transplant/rheumatology team; monitor calcineurin inhibitor trough levels during initiation and adjust dose if needed.
Concurrent phenytoin therapy. Phenytoin is a narrow-therapeutic-index CYP2C9 substrate. Silymarin addition can modestly elevate phenytoin plasma levels. Monitor plasma levels during silymarin initiation and adjust phenytoin dose as needed.
Concurrent statin therapy. Silymarin is a weak OATP1B1 inhibitor, and statins are OATP1B1 substrates. Plasma statin levels can rise modestly (more with rosuvastatin, pravastatin, and pitavastatin than with simvastatin or atorvastatin). Clinically, this interaction is usually insignificant but can occasionally contribute to new myalgia. If new muscle symptoms develop after adding silymarin, pause the silymarin for 2 weeks and reassess; if muscle symptoms resolve, the interaction is likely contributory — dose reduction of either agent is reasonable.
Concurrent hormonal therapy (OCP, HRT, anti-estrogens). Silymarin has been reported to affect estrogen metabolism via UGT modulation in some preclinical studies. Clinical evidence of meaningful interaction with oral contraceptives or hormone replacement therapy is lacking, but a theoretical concern exists. No specific monitoring or avoidance is required at typical silymarin doses.
Hormone-sensitive cancers. Silymarin/silibinin has complex estrogenic and anti-estrogenic effects in preclinical studies. In hormone-sensitive cancers (estrogen-receptor-positive breast cancer, prostate cancer on androgen deprivation therapy), coordinate use with the oncology team — silymarin is not clearly contraindicated and has been studied as a potential adjuvant in some settings, but changes to the supplement regimen should be discussed with the oncologist.
Bleeding disorders. Silymarin has essentially no direct anticoagulant or antiplatelet activity at standard doses. Standard surgical precautions apply — stop 7 days before major elective surgery as a generic precaution, though the clinical risk is minimal.
Children under 12. Limited pediatric data. Small clinical series in pediatric NAFLD and viral hepatitis exist. Safe under pediatrician oversight; not recommended as routine supplementation without specific indication.
Gallstones or acute biliary obstruction. Silymarin has mild choleretic effect (increased bile flow). In confirmed gallstones, this is typically safe and may be beneficial, but in acute biliary obstruction (cholangitis, impacted common bile duct stone), adding silymarin is not the priority — emergency management of the obstruction is. Discuss with gastroenterology.
Contraindications that are NOT present:
- Liver disease: silymarin is INDICATED, not contraindicated. No dose adjustment needed in mild-moderate hepatic impairment. Decompensated cirrhosis should have hepatology oversight but silymarin is typically continued.
- Kidney disease: no dose adjustment needed.
- Cardiovascular disease: no specific contraindication.
- Active infection: no specific contraindication.
- Autoimmune disease: generally safe; coordinate with rheumatology for concurrent immunosuppressant interactions.
- Prior statin intolerance: silymarin is fine alongside statins.
- Thyroid disease: no interaction.
- Mental health conditions, psychiatric medications: no meaningful interaction.
Red flags warranting discontinuation:
- New rash, urticaria, angioedema, or anaphylaxis
- Persistent GI intolerance (nausea, vomiting, severe diarrhea) despite dose reduction and meal timing adjustments
- Unexplained rising liver enzymes (>2x baseline after 8+ weeks of silymarin — investigate for alternate causes but consider product quality as well)
- New-onset hypoglycemia in diabetics requiring repeated rescue glucose
- Unexplained bruising or bleeding
- New muscle pain in statin users
Stop the product, consult your physician, and investigate before resuming.
Not a replacement for prescription hepatic or metabolic therapy. Silymarin is an adjunct. It does not replace: direct-acting antivirals for chronic hepatitis C, nucleos(t)ide analogs for chronic hepatitis B, immunosuppression for autoimmune hepatitis or PBC/PSC, GLP-1 agonists or metformin for diabetes, statins for ASCVD risk reduction, or resmetirom for FDA-indicated NASH treatment. It is a valid and defensible complement to evidence-based prescription therapy under clinician coordination.
Not contraindicated but commonly confused:
- Silymarin is NOT the same as silica (mineral supplement, unrelated)
- Silymarin is NOT the same as milk thistle seed powder (non-standardized, variable potency)
- Silymarin is NOT interchangeable with "liver detox" programs claiming to remove toxins (physiologically inaccurate marketing)
- Silymarin does NOT cause the famous grapefruit-juice drug interaction (that is 3A4-mediated by specific furanocoumarins unique to grapefruit)
- Silybum marianum (milk thistle) is NOT the same plant as Carduus marianus (a related species) despite old taxonomy; modern pharmaceutical silymarin is sourced from Silybum marianum specifically.
Research Disclaimer
This interaction data is compiled from published research and community reports. It may not be exhaustive. Always consult a healthcare professional before combining compounds.
No listings found for Silymarin.
Research Score
5824 PubMed studies
Quality Indicators
Data Completeness
63%Research Credibility
Well-researched compound
Quick Facts
Trial Phase
Preclinical
Research Disclaimer
This information is for educational and research purposes only. Not intended as medical advice. Consult a healthcare professional before use.
Frequently Asked Questions
What exactly is silymarin, and is it different from milk thistle?
Silymarin is the standardized active flavonolignan complex extracted from milk thistle (Silybum marianum) seeds. Milk thistle is the plant; silymarin is the active pharmacologic mixture. Silymarin itself is not a single molecule — it is a defined group of six closely related flavonolignans: silybin A, silybin B (together called silibinin, the most active pair, 50–70% of the silymarin complex), isosilybin A, isosilybin B, silychristin, and silydianin, plus the flavonoid precursor taxifolin. USP-standardized milk thistle extract contains 70–80% silymarin, of which silibinin should constitute at least 30%. Non-standardized 'milk thistle seed' products vary enormously in silymarin content and should be avoided for therapeutic intent. When clinical trials or this page refer to 'silymarin,' they mean standardized extract at defined silibinin content — not random milk thistle seed tea or bulk powder.
Does silymarin actually help the liver, or is it mostly hype?
Silymarin genuinely helps in specific liver contexts, though the effect sizes in common chronic liver disease are modest. The strongest evidence is for amatoxin (death cap mushroom) poisoning — IV silibinin dihydrogensuccinate (Legalon SIL) holds FDA orphan drug designation and is effectively curative when given within 48 hours of ingestion (Mengs 2012 PMID 22208655). In NAFLD/NASH, multiple RCTs show ALT reductions of 10–25% in responders with silybin-phosphatidylcholine phytosome forms (Loguercio 2012, Navarro 2019 PMID 30816904). In alcoholic cirrhosis, Ferenci 1989 (PMID 2671116) showed 4-year survival of 58% with silymarin vs 39% placebo. In chronic hepatitis C, the definitive Fried 2012 trial (PMID 22797851) was null for ALT endpoint, but Hawke's pharmacokinetic work (PMID 19923268) suggests the oral doses achieved didn't reach therapeutic plasma levels. So: silymarin is not a miracle liver drug, but it is one of the most mechanistically well-characterized and safest hepatoprotectants available, with meaningful clinical signals in the most important contemporary indication (NAFLD/MAFLD).
Should I take regular silymarin or the 'phytosome' (silybin-phosphatidylcholine) version?
For therapeutic intent (confirmed NAFLD, NASH, starting hepatotoxic medication, post-acute liver injury recovery), the phytosome form (Siliphos, Realsil, Silybin Advanced) is strongly preferred — it produces 4–10 fold higher plasma silibinin levels than standard extract. For general daily liver support in a healthy user, a well-standardized 80% silymarin extract at 200–300 mg BID is cost-effective and adequate. The phytosome costs 2–4x as much but delivers meaningfully more absorbed active compound. A reasonable rule of thumb: if you have a specific hepatic concern, go phytosome; if you're taking it as general preventive maintenance in someone with healthy labs, standard extract is fine. Brand references for phytosome: Thorne Siliphos, Life Extension European Milk Thistle (Silybin Advanced), Jarrow Milk Thistle Phytosome. For standard extract: Nature's Way Thisilyn, NOW Foods Milk Thistle Silymarin, Solgar Milk Thistle.
Will silymarin help with fatty liver disease (NAFLD/MAFLD)?
Probably yes, modestly. Multiple RCTs have evaluated silymarin in NAFLD with generally positive results. The largest and best-designed trial (Loguercio 2012 multicenter study of Realsil, a silybin-phosphatidylcholine-vitamin E complex) showed significant improvements in ALT, AST, GGT, HOMA-IR, and histologic activity over 12 months in 179 patients. Navarro 2019 (PMID 30816904) in non-cirrhotic NASH showed trend toward fibrosis improvement over 48 weeks of high-dose oral silymarin. A 2017 meta-analysis of 8 RCTs (578 patients) found silymarin reduced ALT by roughly 9 U/L and AST by 6 U/L versus controls — modest but clinically meaningful when applied to a population of millions of NAFLD patients globally. Important context: the primary intervention for NAFLD/MAFLD is lifestyle (7–10% weight loss through diet and exercise, Mediterranean dietary pattern, alcohol minimization). Silymarin is adjunctive to this, not a replacement. For best results, combine silymarin phytosome 240 mg BID with TUDCA, NAC, choline, and a Mediterranean/low-refined-carbohydrate diet. Coordinate with primary care if HbA1c is elevated — newer agents like GLP-1 agonists (semaglutide, tirzepatide) and SGLT2 inhibitors have robust NAFLD benefit and are appropriate prescription options.
Can silymarin protect my liver if I drink alcohol?
Partially, but it is not a license to drink. Silymarin reduces some of the oxidative damage from ethanol metabolism — alcohol is metabolized to acetaldehyde (a toxic intermediate) and generates substantial reactive oxygen species in hepatocytes. Silymarin's antioxidant, glutathione-boosting, and Nrf2-activating mechanisms address some of this oxidative load. In confirmed alcoholic liver disease with continued drinking, Ferenci 1989 showed survival benefit. However, the overwhelming evidence is that alcohol cessation is the primary intervention — silymarin cannot overcome ongoing alcohol-induced liver damage if drinking continues at high levels. For moderate drinkers (≤7 drinks/week for women, ≤14 for men): silymarin 300 mg/day as maintenance is reasonable, combined with Mediterranean diet and adequate nutrition. For users actively dependent on alcohol: addiction treatment, nutritional rehabilitation (thiamine, folate, B12), and medical management are primary; silymarin is an adjunct during recovery. For post-binge protection: a single night of heavy drinking can be partially mitigated with silymarin + NAC + adequate hydration + B-complex the morning after, but the best protection is drinking less.
Does silymarin help with hangovers?
Modestly, with caveats. The hangover is a complex phenomenon involving dehydration, electrolyte disturbance, acetaldehyde accumulation, congener metabolism, mild acidosis, and gut and neurological effects. Silymarin addresses one node — hepatic oxidative stress from ethanol metabolism — but does not meaningfully prevent the other hangover mechanisms. Studies specifically on silymarin for acute hangover are small and mixed. A practical anti-hangover stack based on evidence: (1) hydration with electrolytes before, during, and after drinking, (2) food with fat and protein before drinking, (3) silymarin 300 mg + NAC 600 mg + B-complex before drinking and the morning after, (4) limit congener-rich drinks (dark spirits, red wine), (5) sleep adequately. Silymarin alone is unlikely to prevent a significant hangover from heavy drinking; combined with the above it contributes to a meaningful reduction. The single best hangover intervention is drinking less or not at all.
Is it safe to take silymarin long-term — for years?
Yes, the safety evidence supports indefinite continuous use at standard doses. European clinical experience includes continuous use over years to decades without adverse signals. Ferenci's cirrhosis cohort took silymarin continuously for mean 41 months. NAFLD and chronic hepatitis patients commonly take silymarin for 5–10+ years. The side-effect profile does not escalate with duration — early GI side effects that resolve in the first weeks typically do not return. There is no known tachyphylaxis (loss of effect with continued use), no withdrawal syndrome on discontinuation, no accumulation toxicity, and no meaningful long-term organ concerns. Recommended monitoring during chronic use: comprehensive metabolic panel every 6–12 months (this is good practice regardless of silymarin use), and addressing the underlying liver concern (weight loss, alcohol cessation, viral hepatitis treatment, medication review) as the primary strategy with silymarin as durable support.
Can silymarin interact with my other medications?
Yes, mostly minor but a few worth noting. Silymarin is a weak inhibitor of CYP3A4, CYP2C9, OATP1B1, and P-glycoprotein. Clinically relevant interactions: (1) warfarin — INR may rise modestly; recheck INR 2–3 weeks after starting silymarin. (2) Cyclosporine/tacrolimus in transplant recipients — monitor trough levels during initiation. (3) Phenytoin — monitor plasma levels. (4) Statins, especially rosuvastatin and pitavastatin — statin levels may rise modestly via OATP1B1 inhibition; monitor for new myalgia. (5) Sulfonylureas and insulin — mild additive hypoglycemic effect during first 2–4 weeks; monitor glucose. Clinically insignificant interactions for most users: metformin, GLP-1 agonists, SGLT2 inhibitors, most antihypertensives, SSRIs/SNRIs, bupropion, beta-blockers, calcium channel blockers, PPIs, thyroid hormones, most antibiotics. HCV direct-acting antivirals and HBV nucleos(t)ide analogs have no meaningful interaction and silymarin can be continued through DAA therapy. Always tell your prescribing physician and pharmacist about silymarin use, particularly for narrow-therapeutic-index drugs.
How does silymarin compare to TUDCA, NAC, or other liver supplements?
Different mechanisms, complementary stacking. Silymarin: antioxidant, anti-inflammatory, antifibrotic, hepatocyte membrane stabilization via OATP inhibition, Nrf2 activation. TUDCA: bile acid with FXR-ligand activity, ER-stress reduction, mitochondrial protection — the best single complement to silymarin and arguably the most underrated liver supplement available. NAC (N-acetylcysteine): cysteine substrate for glutathione synthesis; silymarin upregulates the GSH-synthesizing enzyme, NAC provides the substrate. Glutathione direct (liposomal or acetyl-L-): direct antioxidant replenishment. Alpha-lipoic-acid: mitochondrial antioxidant with GSH regeneration. Choline/phosphatidylcholine: VLDL packaging for hepatic triglyceride export — critical in NAFLD. Berberine: metabolic (AMPK, insulin sensitivity, de novo lipogenesis reduction) — the single best metabolic complement to silymarin in NAFLD. Curcumin: anti-inflammatory polyphenol with overlapping hepatoprotective mechanisms. Optimal daily liver stack for NAFLD: silymarin phytosome 240 mg BID + TUDCA 250–500 mg BID + NAC 600 mg BID + choline 500 mg/day + berberine 500 mg BID + Mediterranean diet + exercise. This is a mechanistically comprehensive regimen with strong safety profile.
What should I look for when buying a silymarin / milk thistle supplement?
Three priority criteria. (1) Standardization: the label must specify silymarin percentage (70–80%) and ideally silibinin percentage (at least 30%). Avoid products labeled 'milk thistle seed powder' or 'milk thistle 1000 mg' without specified silymarin content — these vary wildly in potency. (2) Formulation quality: for therapeutic intent, choose a silybin-phosphatidylcholine phytosome form (branded as Siliphos, Realsil, Silybin Advanced) with specified silibinin content per serving. For general support, a well-standardized 80% silymarin extract is adequate. (3) Manufacturer quality: USP-verified, NSF-certified, GMP-manufactured products from reputable brands (Thorne, Life Extension, Pure Encapsulations, Designs for Health, Nature's Way Thisilyn, Jarrow Formulas, NOW Foods, Solgar). Avoid 'proprietary blends' where silymarin content is masked. Avoid very cheap bulk powder products without third-party testing. For therapeutic intent: Thorne Siliphos or Life Extension European Milk Thistle (Silybin Advanced) are excellent choices. For general support: Nature's Way Thisilyn or Jarrow Formulas Milk Thistle at clearly standardized silymarin content. Cost range: standardized extract $10–15/month, phytosome $30–50/month. Price is not a reliable proxy for quality — third-party testing and standardization disclosure are better signals.
Research Tools
Free 2026 Peptide Cheat Sheet — 50 pages, PDF
Dosing, reconstitution, stacks, half-lives, and vendor trust tiers. The reference we wish we had on day one.
